LinkOPH

TOKYO — An implantable device that provides sustained delivery of ranibizumab showed potential for optimal visual and anatomical outcomes, according to one speaker. The device, a port delivery system (PDS) produced by Genentech, addresses the need for successful treatment and reduced burden of frequent visits to the physician’s office, Roman Rubio, MD, head of ophthalmology at Genentech, said at the World Ophthalmology Congress. “It is a refillable, non-biodegradable, long-term drug delivery implant aimed at providing sustained drug release. It is placed in the pars plana beneath the conjunctiva using a (Read more...)

TOKYO — Underdeveloped regions of the world need eye care professionals, such as technicians, nurses and other non-medical staff, who specialize in specific areas and train in specific activities to address needs, according to one speaker. “It takes too much time and resources to train and specialize ophthalmologists who will then be able, for lack of structural resources and the type of services that are mostly needed, to use a minimal part of their skills and knowledge. Ophthalmologists are overqualified for certain tasks, and there are countries that just cannot (Read more...)

Do you ever wonder what our world would be like if one tiny detail was changed years ago? Imagine, if you will, that Mr. Peabody, the genius dog that built a time machine, looked at the dry eye world and the medicines we use. He’s pretty bright, that dog. After all, he figured out how to build a time machine. Let’s say he’s also smart enough to know that surface inflammation is a huge issue in dry eye and that one of the clinical signs we see on the eye (Read more...)

Full Story →

Read more →